Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)

Table 2 Lenalidomide treatment, rates of dose reduction, and discontinuation by age group

Lenalidomide	<65 years (n = 97)^a	≥65 to <75 years (n = 98)	≥75 years (n = 91)
Total dose, mg
Median	2540.0^†	1507.5	1070.0
Range	65.0–13,730.0	30.0–10,295.0	50.0–10,980.0
Number of cycles
Median	17.0^‡	14.0	10.0
Range	1.0–63.0	1.0–64.0	1.0–62.0
Dose reductions, n (%)
Neutropenia	33 (34.0)	31 (31.6)	23 (25.3)
Thrombocytopenia	13 (13.4)^§	20 (20.4)	27 (29.7)
Neutropenia and thrombocytopenia	6 (6.2)	8 (8.2)	9 (9.9)
Treatment discontinuation, n (%)
Any AEs	8 (8.2)^¶	17 (17.3)	18 (19.8)
Lack of therapeutic effect	14 (14.4)	12 (12.2)	10 (11.0)
Death	2 (2.1)	4 (4.1)	8 (8.8)

AE adverse event
^† p = 0.001 vs. ≥75 years; p = 0.045 vs. ≥65 to <75 years; ^‡ p = 0.002 vs. ≥75 years; ^§ p = 0.008 vs. ≥75 years; ^¶ p = 0.033 vs. ≥75 years
^aOne patient in the <65 years group was later diagnosed with acute myeloid leukemia, which had been present at the start of the study

ISSN: 1756-8722